Comparative Pharmacology
Head-to-head clinical analysis: CIPRO HC versus XIFYRM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIPRO HC versus XIFYRM.
CIPRO HC vs XIFYRM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ciprofloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing DNA replication and transcription; hydrocortisone suppresses inflammation via glucocorticoid receptor activation.
XIFYRM is a monoclonal antibody that targets and neutralizes interleukin-36 (IL-36), thereby inhibiting the inflammatory signaling cascade involved in pustular psoriasis.
Instill 3 drops into the affected ear(s) twice daily (morning and evening) for 7 days.
500 mg orally twice daily with food.
None Documented
None Documented
Ciprofloxacin: 4-6 hours (prolonged to 6-9 hours in elderly or renal impairment). Hydrocortisone: 1-2 hours.
Terminal elimination half-life: 15 hours; prolonged in renal impairment (creatinine clearance <30 mL/min) to 30 hours
Ciprofloxacin: ~50-70% excreted renally as unchanged drug, ~15% as metabolites; ~20-30% eliminated via biliary/fecal route. Hydrocortisone: metabolized hepatically, renal excretion of metabolites.
Renal: 70% unchanged; Fecal: 20%; Biliary: <10%
Category C
Category C
Antibiotic/Corticosteroid Combination (Otic)
Antibiotic